9 results
1. To improve the overall outcome as compared to the previous protocols of the DCOG, especially ALL-9 and ALL-10. This is aimed for by decreasing therapy for part of the patients (TEL/AML1, Down syndrome, PPR only), increasing therapy for IKZF1…
A decrease in the incidence of central line-associated bloodstream infections in the investigational study group, compared to the control group.
At least 90% of the subjects, with 95% confidence, will tolerate the test formula.
PRIMARY OBJECTIVE: -To assess the antibody response after mRNA (Pfizer, Moderna) SARS-CoV-2 vaccination in children with cancer SECONDARY OBJECTIVES: To assess in children with cancer after SARS-CoV 2 vaccination: - durability of…
The aim of our descriptive study was to quantify the disease burden leading to hospital-based care, repatriation or death in Dutch travelers during their stay in a foreign country, including Europe. The outcome of this study could be used as…
Primary Objectives: -To evaluate if the treatment of Low Risk HB can be reduced (Group B1) -To compare different induction treatment regimens for Intermediate risk HB (Group C) -To compare different post induction treatment regimens for…
Primary objectives: - Overall: Improvement of event-free survival (EFS) probabilities in childhood relapsed ALL - Randomization 1: EFS of Arm A (ALL-REZ BFM 2002) versus B (ALLR3) in SR patients - Randomization 2: Influence of epratuzumab…
To analyze the number of patients with (germline/somatic) actionable molecular aberrations in patients with relapsed/refractory pediatric tumors for whom no standard treatment or study protocol is available.
Primary Objective: - Achieving an event-free survival, which is not inferior to the ML-DS 2006 trial (87±3%) Secondary Objective(s): - Reduction of toxicity: severe adverse events (CTCAE v4.0 grade III or higher) - Evaluation of…